about
Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborationsAnaemia in acute HIV-1 subtype C infectionEstablishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study.Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort studyImpact of antiretroviral therapy on health-related quality of life among South African women in the CAPRISA 002 acute infection study.HIV prevention in high-risk women in South Africa: condom use and the need for change.Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trialFluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression.Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trialPlasma cytokine levels during acute HIV-1 infection predict HIV disease progression.Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testingRapid disease progression in HIV-1 subtype C-infected South African women.A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South AfricaRisk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting.Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set pointAssessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.HIV transmission risk behavior among HIV-positive patients receiving antiretroviral therapy in KwaZulu-Natal, South AfricaDeveloping a globally applicable evidence-informed competency framework to support capacity strengthening in clinical research.Introducing 'global health methodology research' a knowledge sharing platform open to all.A research methodology study to map the process of initiating and operating a randomised controlled trial of podoconiosis treatment in Northern Ethiopia.Perspective conducting HIV prevention research in South Africa.Relationship between Levels of Inflammatory Cytokines in the Genital Tract and CD4+Cell Counts in Women with Acute HIV‐1 Infection
P50
Q28652262-5DBC92EF-20E7-4047-A227-18C895FE69BFQ33320529-2597CB9B-64D0-4061-8C65-B27949DB3C4DQ33328477-8754712B-FA54-4B06-9108-5A42AD62500FQ33610865-7D98A3B8-5195-4C32-8595-E23353663A91Q34021927-6D206E10-21C0-4239-8AC0-86ACF0DEB3F9Q34170153-006E5B94-3ACC-48A9-A4B7-443108959F0DQ34288207-D2F60FA5-3536-4AF5-A0AE-345828C1F73BQ34295981-BC410A58-B50F-4308-A6C4-502B130EFB37Q34320878-C9A0E3E5-1966-437E-A09C-F091206B6623Q34402041-7F314B1A-BD9E-444A-BD8C-5628D1D4F421Q34706934-D47D58BB-629B-4450-AE0C-46B835C52367Q34736181-91AF04E8-785D-41CC-8E9C-7BF2F65F39C7Q35540921-56F89079-612F-43D6-8727-967E07EB3C20Q35862772-032BE142-696A-449B-9E8F-EFE28B94C506Q36376181-A281E6CC-CF0D-487E-B642-4755ABF69383Q37033201-194E9E67-7A8C-4C2E-A244-26214C9F0465Q37699140-AC1F4DDB-3957-4D34-9DF3-8691FC7D3A61Q37724841-25645A28-5962-4188-940C-309FBF076C83Q39113063-7798780B-0748-4B3A-B73D-ACF3C90B2879Q46408207-DD09C3F5-613D-42F2-83A5-46B160293D3BQ46428530-7CB59C2C-82F0-4D81-BABE-E4E5491107A5Q46656217-C5D0A438-A412-481B-9350-FEA60DADC672Q56989563-12DBE611-2B6F-4E99-962F-0667BC5F1FBC
P50
name
Francois van Loggerenberg
@en
Francois van Loggerenberg
@nl
type
label
Francois van Loggerenberg
@en
Francois van Loggerenberg
@nl
prefLabel
Francois van Loggerenberg
@en
Francois van Loggerenberg
@nl